Erelzi is a copy of Amgen’s best-selling psoriasis drug Enbrel. Amgen filed a lawsuit against Novartis, claiming it has patent protection on Enbrel until 2029.
Richard Francis, head of Novartis’ generic drug unit Sandoz, said it will take at least another year to resolve the legal battle, according to the report.
“That won’t really reach a conclusion until 2018,” Mr. Francis told Reuters. “That’s the frustration sometimes of the legal situation, but the way I look at that, we’re carving the landscape out as we go.”
Novartis and Amgen are also involved in a separate lawsuit on whether drug companies must wait six months after winning regulatory approval before selling biosimilars.
More articles on supply chain:
7 must-reads for supply chain leaders this week
Trump holds phone call with Sen. Cummings on high drug costs
How prescription drug prices are set: 6 takeaways
